Technical Analysis for DVAX - Dynavax Technologies Corporation

Grade Last Price % Change Price Change
grade F 4.38 0.46% 0.02
DVAX closed down 2.68 percent on Monday, September 28, 2020, on 43 percent of normal volume. Due to the stock's strong downtrend, it may remain oversold for a while. So, if you're looking for a reason to buy, don't put too much weight on it being oversold.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Strong Down Down Down
Historical DVAX trend table...

Date Alert Name Type % Chg
Wide Bands Range Expansion 0.46%
Oversold Stochastic Weakness 0.46%
MACD Bearish Signal Line Cross Bearish -2.23%
NR7 Range Contraction -2.23%
Wide Bands Range Expansion -2.23%
Oversold Stochastic Weakness -2.23%
Stochastic Reached Oversold Weakness 1.39%
Wide Bands Range Expansion 1.39%
Below Lower BB Weakness 1.39%
Down 3 Days in a Row Weakness 1.39%
Older End-of-Day Gignals for DVAX ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
Up 2% about 3 hours ago
Up 1% about 3 hours ago
Fell Below Previous Day's Low 1 day ago
Lower Bollinger Band Support 1 day ago
Down 3% 1 day ago
View Earlier Intraday Alerts

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Dynavax Technologies Corporation, a clinical-stage biopharmaceutical company, discovers and develops novel products to prevent and treat infectious and inflammatory diseases. It develops product candidates based on the use of immunostimulatory sequences and immunoregulatory sequences. Its lead product candidate is HEPLISAV, a Phase III investigational adult hepatitis B vaccine. The company also develops DV1179, a Phase I bifunctional inhibitor of TLR7 and TLR9 for the treatment of autoimmune and inflammatory diseases; and AZD1419, a preclinical drug candidate for the treatment of asthma. It has a strategic alliance with GlaxoSmithKline to discover, develop, and commercialize TLR inhibitors; and a research collaboration and license agreement with AstraZeneca AB for the discovery and development of TLR9 agonist-based therapies for the treatment of asthma and chronic obstructive pulmonary disease. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. Dynavax Technologies Corporation was founded in 1996 and is based in Berkeley, California.
Biopharmaceutical Health Pharmaceutical Industry Asthma Astrazeneca Autoimmune And Inflammatory Diseases Chronic Obstructive Pulmonary Disease Treatment Of Autoimmune And Inflammatory Diseases Novel Products Tlr7 Tlr9

Is DVAX a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 12.44
52 Week Low 1.8
Average Volume 5,046,203
200-Day Moving Average 5.69
50-Day Moving Average 6.77
20-Day Moving Average 5.12
10-Day Moving Average 4.95
Average True Range 0.48
ADX 27.75
+DI 15.80
-DI 29.28
Chandelier Exit (Long, 3 ATRs ) 4.84
Chandelier Exit (Short, 3 ATRs ) 5.67
Upper Bollinger Band 6.05
Lower Bollinger Band 4.20
Percent B (%b) 0.09
BandWidth 36.15
MACD Line -0.56
MACD Signal Line -0.56
MACD Histogram -0.0078
Fundamentals Value
Market Cap 239.1 Million
Num Shares 54.8 Million
EPS -2.42
Price-to-Earnings (P/E) Ratio -1.80
Price-to-Sales 143.85
Price-to-Book 7.89
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.78
Resistance 3 (R3) 4.79 4.67 4.71
Resistance 2 (R2) 4.67 4.56 4.66 4.69
Resistance 1 (R1) 4.51 4.49 4.45 4.50 4.66
Pivot Point 4.39 4.39 4.36 4.38 4.39
Support 1 (S1) 4.23 4.28 4.17 4.22 4.06
Support 2 (S2) 4.11 4.21 4.10 4.03
Support 3 (S3) 3.95 4.11 4.01
Support 4 (S4) 3.94